Merger Remedies in China in 2022 and the Prevalence of “Continue to Supply Under Frand Principles” as the Remedies

This Article examines the remedy imposed on the conditional approvals in China’s merger review in 2022. The five cases of conditional approvals in 2022 are summarised from both procedural and substantive perspectives with the behavioural remedy of “continue to supply under FRAND principles” highlighted. This article studies the prevalence of the remedy of “continue to supply under FRAND principles” in the recent years and analyses SAMR’s reasoning behind. The prevalence of “continu